Using drugs that target the unique metabolic dependencies of specific tumors (e.g., OXPHOS inhibitors, glutaminase inhibitors) could slow tumor growth and potentially reduce the tumor’s nutrient consumption, indirectly “freeing up” metabolites in the TME for use by CAR T cells. Here, GLS is linked to neoplasm.